103 related articles for article (PubMed ID: 26796853)
21. The clinicopathological significance and drug target potential of FHIT in breast cancer, a meta-analysis and literature review.
Su Y; Wang X; Li J; Xu J; Xu L
Drug Des Devel Ther; 2015; 9():5439-45. PubMed ID: 26491255
[TBL] [Abstract][Full Text] [Related]
22. The clinicopathological significance of FHIT hypermethylation in non-small cell lung cancer, a meta-analysis and literature review.
Yan W; Xu N; Han X; Zhou XM; He B
Sci Rep; 2016 Jan; 6():19303. PubMed ID: 26796853
[TBL] [Abstract][Full Text] [Related]
23. The clinicopathological significance and ethnic difference of FHIT hypermethylation in non-small-cell lung carcinoma: a meta-analysis and literature review.
Wu X; Wu G; Yao X; Hou G; Jiang F
Drug Des Devel Ther; 2016; 10():699-709. PubMed ID: 26929601
[TBL] [Abstract][Full Text] [Related]
24. Aberrant methylation of the FHIT gene in chronic smokers with early stage squamous cell carcinoma of the lung.
Kim JS; Kim H; Shim YM; Han J; Park J; Kim DH
Carcinogenesis; 2004 Nov; 25(11):2165-71. PubMed ID: 15231689
[TBL] [Abstract][Full Text] [Related]
25. Clinicopathological significance and potential drug target of RUNX3 in non-small cell lung cancer: a meta-analysis.
Xu L; Lan H; Su Y; Li J; Wan J
Drug Des Devel Ther; 2015; 9():2855-65. PubMed ID: 26082616
[TBL] [Abstract][Full Text] [Related]
26. Clinicopathological significance and potential drug target of T-cadherin in NSCLC.
Wang Z; Wang B; Guo H; Shi G; Hong X
Drug Des Devel Ther; 2015; 9():207-16. PubMed ID: 25565774
[TBL] [Abstract][Full Text] [Related]
27. FHIT promoter methylation status, low protein and high mRNA levels in patients with non-small cell lung cancer.
Czarnecka KH; Migdalska-Sęk M; Domańska D; Pastuszak-Lewandoska D; Dutkowska A; Kordiak J; Nawrot E; Kiszałkiewicz J; Antczak A; Brzeziańska-Lasota E
Int J Oncol; 2016 Sep; 49(3):1175-84. PubMed ID: 27572663
[TBL] [Abstract][Full Text] [Related]
28. Meta-analyses of gene methylation and smoking behavior in non-small cell lung cancer patients.
Huang T; Chen X; Hong Q; Deng Z; Ma H; Xin Y; Fang Y; Ye H; Wang R; Zhang C; Ye M; Duan S
Sci Rep; 2015 Mar; 5():8897. PubMed ID: 25754026
[TBL] [Abstract][Full Text] [Related]
29. Assessment of the prognostic value of methylation status and expression levels of FHIT, GSTP1 and p16 in non-small cell lung cancer in Egyptian patients.
Haroun RA; Zakhary NI; Mohamed MR; Abdelrahman AM; Kandil EI; Shalaby KA
Asian Pac J Cancer Prev; 2014; 15(10):4281-7. PubMed ID: 24935385
[TBL] [Abstract][Full Text] [Related]
30. Fragile histidine triad (FHIT) suppresses proliferation and promotes apoptosis in cholangiocarcinoma cells by blocking PI3K-Akt pathway.
Huang Q; Liu Z; Xie F; Liu C; Shao F; Zhu CL; Hu S
ScientificWorldJournal; 2014; 2014():179698. PubMed ID: 24757411
[TBL] [Abstract][Full Text] [Related]
31. DNA methylation pattern as important epigenetic criterion in cancer.
Ghavifekr Fakhr M; Farshdousti Hagh M; Shanehbandi D; Baradaran B
Genet Res Int; 2013; 2013():317569. PubMed ID: 24455281
[TBL] [Abstract][Full Text] [Related]
32. Promoter methylation status of the FHIT gene and Fhit expression: association with HER2/neu status in breast cancer patients.
Jeong YJ; Jeong HY; Lee SM; Bong JG; Park SH; Oh HK
Oncol Rep; 2013 Nov; 30(5):2270-8. PubMed ID: 23969757
[TBL] [Abstract][Full Text] [Related]
33. The role of DNA methylation as biomarkers in the clinical management of lung cancer.
Fleischhacker M; Dietrich D; Liebenberg V; Field JK; Schmidt B
Expert Rev Respir Med; 2013 Aug; 7(4):363-83. PubMed ID: 23964627
[TBL] [Abstract][Full Text] [Related]
34. DNA methylation and cancer diagnosis.
Delpu Y; Cordelier P; Cho WC; Torrisani J
Int J Mol Sci; 2013 Jul; 14(7):15029-58. PubMed ID: 23873296
[TBL] [Abstract][Full Text] [Related]
35. Reduced FHIT expression is associated with mismatch repair deficient and high CpG island methylator phenotype colorectal cancer.
Al-Temaimi RA; Jacob S; Al-Ali W; Thomas DA; Al-Mulla F
J Histochem Cytochem; 2013 Sep; 61(9):627-38. PubMed ID: 23797051
[TBL] [Abstract][Full Text] [Related]
36. DNA methylation data analysis and its application to cancer research.
Ma X; Wang YW; Zhang MQ; Gazdar AF
Epigenomics; 2013 Jun; 5(3):301-16. PubMed ID: 23750645
[TBL] [Abstract][Full Text] [Related]
37. Quantitative assessment of lung cancer associated with genes methylation in the peripheral blood.
Tan S; Sun C; Wei X; Li Y; Wu Y; Yan Z; Feng F; Wang J; Wu Y
Exp Lung Res; 2013; 39(4-5):182-90. PubMed ID: 23614702
[TBL] [Abstract][Full Text] [Related]
38. Promoter methylation of DAPK1, FHIT, MGMT, and CDKN2A genes in cervical carcinoma.
Banzai C; Nishino K; Quan J; Yoshihara K; Sekine M; Yahata T; Tanaka K;
Int J Clin Oncol; 2014 Feb; 19(1):127-32. PubMed ID: 23494221
[TBL] [Abstract][Full Text] [Related]
39. Trends in cancer mortality in China: an update.
Guo P; Huang ZL; Yu P; Li K
Ann Oncol; 2012 Oct; 23(10):2755-2762. PubMed ID: 22492700
[TBL] [Abstract][Full Text] [Related]
40. The tumour suppressor Fhit positively regulates MHC class I expression on cancer cells.
Romero I; Martinez M; Garrido C; Collado A; Algarra I; Garrido F; Garcia-Lora AM
J Pathol; 2012 Jul; 227(3):367-79. PubMed ID: 22451343
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
